Noida Chronicle

DelveInsight’s, “Sjogren’s Syndrome Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Sjogren’s Syndrome pipeline landscape. It covers the Sjogren’s Syndrome pipeline drugs profiles, including clinical and nonclinical stage products. It also covers the Sjogren’s Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Sjogren’s Syndrome Pipeline @ https://www.delveinsight.com/sample-request/sjogrens-syndrome-pipeline-insight

Key Takeaways from the Sjogren’s Syndrome Pipeline Report

• On June 22, 2026- Lubris Bio Pty Ltd initiated a phase II study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with Sjögren’s related Dry Eye Disease.
• On June 17, 2026- Novartis Pharmaceuticals highlighted a phase 3 study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjogren’s syndrome. The purpose of this study is to demonstrate the clinical efficacy, safety and tolerability of ianalumab (VAY736) administered subcutaneously (s.c.) monthly or every 3 months compared to placebo in patients with active Sjogren’s syndrome.
• On June 16, 2026- Instituto Grifols, S.A. conducted a Phase 2, multi-site, double-masked, randomized, vehicle-controlled, study designed to evaluate the safety, tolerability, and efficacy in adult participants with DED.
• On June 08, 2026- Immunovant Sciences GmbH announced a a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren’s disease (SjD).
• On June 05, 2026- Janssen Research & Development LLC conducted a phase 3 study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren’s disease (SjD). This clinical development program for nipocalimab in SjD includes 2 identical double blind, placebo-controlled studies to evaluate the efficacy, safety, and tolerability of nipocalimab in participants greater than or equal to (>=) 18 years of age with moderate to severe SjD.
• On June 04, 2026- Vor Biopharma initiated a Phase 3 Study to Evaluate the Efficacy and Safety of Telitacicept in Adult Participants With Active Primary Sjögren’s Disease. Telitacicept (RC18) is a recombinant fusion protein designed to target B-cell-mediated immune pathways. It consists of the extracellular domain of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) linked to the Fc portion of human immunoglobulin G1 (IgG1).
• DelveInsight’s Sjogren’s Syndrome pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Sjogren’s Syndrome treatment.
• The leading Sjogren’s Syndrome Companies such as Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici, Amgen, and others.
• Promising Sjogren’s Syndrome Pipeline Therapies such as Baricitinib, Hydroxychloroquine, HZN-1116, Nipocalimab, RSLV-132, Lanraplenib, Filgotinib and others.

Stay ahead with the most recent Sjögren’s Disease Pipeline Outlook Report@ Sjogren’s Syndrome Treatment Drugs

Sjögren’s Disease Overview

Sjogren’s syndrome (SS) is a chronic autoimmune disease with a specific predisposition for causing inflammation of the exocrine glands, predominantly the salivary and lacrimal glands, including the nose, upper respiratory tract, and oropharynx. In SS, the immune system inappropriately attacks various cells, leading to activation of the various pathways, and resulting in inflammation. The main consequence of this inflammation is the development of sicca symptoms due to damage to the salivary and tear glands, such as dryness of the mucosal surfaces, principally in the mouth and eyes. If cytokines, chemokines and autoantibodies are expressed by the epithelium of the exocrine glands: Increased levels of cytokines, chemokine, and autoantibodies expressed by the epithelium of the exocrine glands (such as the salivary and lacrimal glands) lead to chronic inflammation and the eventual loss of their physiological functions.

Sjogren’s syndrome Emerging Drugs Profile

• VAY736: Novartis

VAY736 (ianalumab) is a novel, intravenous, defucosylated, human IgG1/κ monoclonal antibody that targets the human B cell-activating factor (BAFF) of the TNF family. The BAFF receptor is predominantly expressed on B cells and is critically involved in B cell maturation, activation, and survival. VAY736 targets the BAFF receptor and competitively inhibits BAFF binding to BAFF-R, thereby blocking BAFF-R-mediated signaling in B cells. It is also engineered to effectively eliminate B cells from circulation in vivo by antibody-dependent cellular cytotoxicity (ADCC). The ADCC activity of ianalumab is greatly enhanced by eliminating fucose residues from the carbohydrate moiety attached to the Fc part of the antibody. The molecule is being developed by Novartis in partnership with MorphoSys as an antibody-based therapy. The drug is currently in Phase III clinical studies for the treatment of Sjögren’s Syndrome (SS).

• AMG 329: Amgen

AMG 329 is a fully human monoclonal antibody that binds and neutralizes the function of the FLT3-ligand, thereby reducing both conventional and plasmacytoid dendritic cells. The drug is currently in Phase II clinical studies for the treatment of Sjögren’s Syndrome.

• R-2487: Rise Therapeutics

R-2487 is a targeted oral immune therapy that has the ability to induce T regulatory cell populations. R-2487 has a unique mechanism of action by which it can engage specific immune pathways that regulate tolerance and reset T regulatory deficiencies to reduce specific inflammatory cytokines that contribute to autoimmune disease. This mechanism is particularly important in the context of treating autoimmune disease. The drug is currently in Phase I clinical studies for the treatment of Sjögren’s Syndrome.

Explore groundbreaking therapies and clinical trials in the Sjogren’s Syndrome Pipeline @ New Sjogren’s Syndrome Drugs

The Sjogren’s Syndrome Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Sjogren’s Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sjogren’s Syndrome Treatment.
• Sjogren’s Syndrome Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Sjogren’s Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sjogren’s Syndrome market

Sjogren’s Syndrome Companies

Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici, Amgen, and others.

Learn about new Sjögren’s Disease Drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Sjogren’s Syndrome Market Drivers and Barriers

Sjogren’s syndrome Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Sjögren’s Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Sjogren’s Syndrome Pipeline Report

• Coverage- Global
• Sjogren’s Syndrome Companies- Novartis, Horizon Therapeutics, Bristol-Myers Squibb, Rise Therapeutics, Resolve Therapeutics, Dompe Farmaceutici, Amgen, and others.
• Sjogren’s Syndrome Pipeline Therapies- Baricitinib, Hydroxychloroquine, HZN-1116, Nipocalimab, RSLV-132, Lanraplenib, Filgotinib and others.
• Sjogren’s Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Sjogren’s Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Sjogren’s Syndrome Therapies and clinical trials @ Sjogren’s Syndrome Companies, Key Products and Unmet Needs

Table of Content

1. Introduction
2. Executive Summary
3. Sjogren’s syndrome: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Sjogren’s syndrome– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. VAY736: Novartis
9. Mid Stage Products (Phase II)
10. AMG 329: Amgen
11. Early Stage Products (Phase I)
12. R-2487: Rise Therapeutics
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Sjogren’s syndrome Key Companies
17. Sjogren’s syndrome Key Products
18. Sjogren’s syndrome- Unmet Needs
19. Sjogren’s syndrome- Market Drivers and Barriers
20. Sjogren’s syndrome- Future Perspectives and Conclusion
21. Sjogren’s syndrome Analyst Views
22. Sjogren’s syndrome Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/sjogrens-syndrome-pipeline-insight